Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.40 |
| ▸ | RELA | Q04206 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13051430 | 0.81 | ALOX5 (0.41) | ALOX5NISCHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2006177 | 0.81 | ALOX5 (0.45) | ALOX5NISCHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL34471543 | 0.75 | HTR2C (0.31) | ALOX5PTGS1PTGS2 | |
| SCHEMBL20839736 | 0.75 | MMP12 (0.35) | ALOX5NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL20839498 | 0.75 | MMP12 (0.38) | NPC1RAB9ASMN1; SMN2MAPTNFKB1 | |
| SCHEMBL19054488 | 0.75 | TSHR (0.33) | — | |
| SCHEMBL9692516 | 0.75 | TLR2 (0.35) | ALOX5MAPTMEN1KMT2AKDM4E | |
| SCHEMBL8831274 | 0.74 | ALOX5 (0.40) | ALOX5NISCHNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20582126 | 0.73 | KDM4E (0.35) | SMN1; SMN2MAPTKMT2AKDM4EMAOA | |
| SCHEMBL545307 | 0.72 | MTNR1A (0.49) | ALOX5NPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119708027-A | Method for preparing boronated carbonyl derivative | 中国科学院大连化学物理研究所 | 2025-03-28 | — | — | CN | claimed |
| CN-118380656-B | Electrolyte and lithium-sulfur battery | 蜂巢能源科技股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118380656-A | Electrolyte and lithium-sulfur battery | 蜂巢能源科技股份有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-116730967-A | Synthesis method of chroman-3-formic acid | 安徽大学 | 2023-09-12 | — | — | CN | claimed |
| US-20120088923-A1 | METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2012-04-12 | — | — | US | claimed |
| EP-0184801-B1 | CHROMENE DERIVATIVE, PROCESS FOR PREPARING THE SAME AND ANTIALLERGIC AGENT CONTAINING THE SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 1990-09-26 | — | — | EP | claimed |
| EP-0184801-A1 | Chromene derivative, process for preparing the same and antiallergic agent containing the same | Kaken Pharmaceutical Co., Ltd. (JP) | 1986-06-18 | — | — | EP | claimed |
| JP-61137881-A | — | — | None | — | — | JP | disclosed |
| EP-4703358-A1 | BENZO SIX-MEMBERED HETEROCYCLIC GSPT1 PROTEIN DEGRADATION AGENT AND USE THEREOF | China Pharmaceutical University (CN) | 2026-03-04 | — | — | EP | disclosed |
| WO-2025092775-A1 | PHTHALAZINONE GSPT1 PROTEIN DEGRADING AGENT AND USE THEREOF | 中国药科大学 | 2025-05-08 | — | — | WO | disclosed |
| CN-119912437-A | Phthalazinone GSPT protein degradation agent and application thereof | 中国药科大学 | 2025-05-02 | — | — | CN | disclosed |
| WO-2025034810-A1 | SYNTHESES AND USE OF POTASSIUM CHANNEL BLOCKERS IN PET IMAGING AND IN THERAPEUTICS | THE GENERAL HOSPITAL CORPORATION (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024222918-A1 | BENZO SIX-MEMBERED HETEROCYCLIC GSPT1 PROTEIN DEGRADATION AGENT AND USE THEREOF | 中国药科大学 | 2024-10-31 | — | — | WO | disclosed |
| WO-1996020296-A1 | USE OF CHROMIUM DERIVATIVES AS BRIGHTENERS | BASF AKTIENGESELLSCHAFT (DE) | 1996-07-04 | — | — | WO | disclosed |
| US-5112855-A | Nootropic Agents | CIBA-GEIGY CORPORATION (US) | 1992-05-12 | — | — | US | disclosed |
| EP-0184801-B1 | CHROMENE DERIVATIVE, PROCESS FOR PREPARING THE SAME AND ANTIALLERGIC AGENT CONTAINING THE SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 1990-09-26 | — | — | EP | disclosed |
| US-4957928-A | NOOTROPIC AGENTS, COGNITION ACTIVATORS | CIBA-GEIGY CORPORATION (US) | 1990-09-18 | — | — | US | disclosed |
| US-4731375-A | Coumarin derivatives and antiallergic agents containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
| JP-S61137881-A | CHROMENE DERIVATIVE, ITS PREPARATION AND ANTIALLERGIC CONTAINING SAME AS AN ACTIVE INGREDIENT | KAKEN PHARMACEUT CO LTD | 1986-06-25 | — | — | JP | disclosed |
| EP-0184801-A1 | Chromene derivative, process for preparing the same and antiallergic agent containing the same | Kaken Pharmaceutical Co., Ltd. (JP) | 1986-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088923-A1 | METHOD FOR PREPARING A COUMARIN COMPOUND, CHROMENE COMPOUND, AND METHOD FOR PREPARING A CHROMENE COMPOUND | CYP3A7, CYP2A7, F7 | ALOX5 1360/4885NISCH 59/4885NPC1 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.